Uncategorized

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

​Read More

Published

on

The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version